CBRE vs COLL · P/E 43, rev $35.77B vs P/E 17, rev $181.9M
CBRE Group Inc Class A (CBRE) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the CBRE and COLL stock pages for the full models.
Not investment advice.